Background {#Sec1}
==========

Type 1 diabetes mellitus (T1DM) is a globally-widespread disease that is characterized by a reduction in insulin production or the production of ineffective insulin \[[@CR1]\]. It is generally believed that the immune-associated destruction of beta cells of the islets of Langerhans causes the disease, resulting in lower insulin levels (that is called type 1a diabetes mellitus). In a smaller T1DM subset, no evidence of autoimmunity can be found (type 1b) \[[@CR2]\]. T1DM constitutes roughly 5 to 10% of all diabetes cases, and its prevalence is still rising \[[@CR3]\]. With more than half a million children living with T1DM, and almost 90,000 children diagnosed each year, T1DM inflicts mostly children of under 15 years of age \[[@CR4]\]. It is well known that T1DM is a multi-factorial autoimmune disorder caused by interactions between genetic and environmental factors \[[@CR5]\].

Vitamin D (VitD) is a steroid molecule that has many roles in the body, such as regulation of the immune cells. In addition to immune responses, VitD is also involved in the etiopathogenesis of several disorders, such as cancer, autoimmune disorders, cardiovascular disorders, asthma, and diabetes \[[@CR6]--[@CR9]\]. In animal model of T1DM, VitD suppresses the occurrence of diabetes, by regulating the T helper (Th) 1/Th2 cytokine balance in the local pancreatic lesions \[[@CR10], [@CR11]\]. Moreover, VitD inhibits T cell activation and secretion of pro-inflammatory cytokines, such as interleukin (IL)-1, IL-6, IL-12, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ, which are involved in the pathogenesis of T1DM \[[@CR12]--[@CR14]\]. Mostly, VitD exerts its function through vitamin D receptor (VDR), which is found in the nuclei of target cells, such as lymphocytes, macrophages, and pancreatic cells. VDR is a member of the nuclear hormone receptors superfamily and has been linked to insulin sensitivity and secretion \[[@CR15]\].

Four common single nucleotide polymorphisms (SNPs) of VDR gene are FokI (rs2228570), TaqI (rs731236), BsmI (rs1544410), and ApaI (rs7975232). Among them, ApaI, BsmI, and TaqI polymorphisms are located in the 3′-end of *VDR* gene which lead to silent mutation associated with increased *VDR* mRNA stability. In contrast, FokI SNP is located in the start codon that produces a protein with shorter size (424 amino acids), which is more active than the long form (427 amino acids) \[[@CR8], [@CR16], [@CR17]\]. Over the course of past few decades, the VDR gene polymorphisms have been associated with susceptibility to numerous autoimmune disorders \[[@CR8], [@CR18], [@CR19]\].

In recent years, several studies have investigated the association between *VDR* gene SNPs and T1DM in all over the world, which have yielded conflicting results. The reasons for these discrepancies might be small sample sizes, clinical heterogeneity, and low statistical power. Therefore, a comprehensive meta-analysis might be the best way to solve these problems. Two previous meta-analyses performed by Tizaouia et al. in 2014 \[[@CR20]\] and Guo et al. in 2006 \[[@CR21]\] reported that *VDR* gene polymorphisms were not associated with the susceptibility to T1DM. However, Zhang et al. in 2012 \[[@CR22]\] demonstrated that BsmI polymorphism was significantly associated with the risk of T1DM. Furthermore, Sahin et al. in 2017 indicated that BsmI and TaqI polymorphisms were associated withT1DM risk in children with less than average 15 years old \[[@CR23]\]. Qin et al. in 2014 evaluated the association of only BsmI SNP with T1DM risk and demonstrated its association in the overall analysis, as well as in Asians, Latino, and Africans \[[@CR24]\]. In 2014, Wang et al., by including 20 studies, reported that BsmI polymorphism might be a risk factor for susceptibility to T1DM in the East Asian population, and the FokI polymorphism was associated with an increased risk of T1DM in the West Asian population \[[@CR25]\].

Since several articles published after the last meta-analysis, here we conducted an updated meta-analysis with the aim of providing a much more reliable conclusion on the significance of the association between *VDR* gene polymorphisms and T1DM risk.

Methods {#Sec2}
=======

This meta-analysis was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, including search strategy, inclusion and exclusion criteria, data extraction and quality assessment, and statistical analysis \[[@CR26]\].

Search strategy {#Sec3}
---------------

Three electronic databases (PubMed/MEDLINE, Scopus, and Web of Science) were systematically searched for studies regarding the association of *VDR* gene polymorphisms, including FokI (rs2228570) and/or TaqI (rs731236) and/or BsmI (rs1544410) and/or ApaI (rs7975232), and T1DM susceptibility, which were published before May 2020. The following combinations of search terms were used: ("T1D" OR "type 1 diabetes" OR "diabetes") AND ("VDR" OR "vitamin D receptor") AND ("polymorphisms" OR "SNP" OR "variation" OR "mutation"). The reference lists of review articles were also manually searched for additional pertinent publications. Original data in English language and human population studies were collected.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Eligible studies must meet the following criteria: a) All studies assessing the association of *VDR* gene polymorphisms and T1DM risk; b) All studies reporting sufficient data to calculate the odds ratio (OR) and its 95% confidence intervals (CIs); c) All studies with distinct case and control groups (case-control and cohort design). The exclusion criteria were: a) studies that their genotype or allele frequency could not be extracted; b) letters, non-English publications, animal studies, case reports, reviews, comments, book chapters, and abstracts; c) duplicate and republished studies. The application of these criteria recognized 39 studies eligible for the quantitative analysis.

Data extraction and quality assessment {#Sec5}
--------------------------------------

According to a standardized extraction form, the following data were independently extracted by two reviewers: the author's name, journal and year of publication, country of origin, ethnicity, number of case and control for each gender separately, genotype and allele frequencies in cases and healthy groups, mean or range of age, genotyping method, total sample size of cases and controls. The third reviewer finalized the extracted data, and potential discrepancies were resolved by consensus. For quality assessment of the included publications, the Newcastle-Ottawa Scale (NOS) was applied \[[@CR27]\]. In this respect, studies with 0--3, 4--6 or 7--9 scores were, respectively, of low, moderate, and high-quality.

Statistical analysis {#Sec6}
--------------------

Deviation from Hardy--Weinberg equilibrium (HWE) for distribution of the allele frequencies was analyzed by χ2-test in control groups. The strength of association between *VDR* gene polymorphisms and T1DM susceptibility was estimated by calculating pooled OR and its 95% CI. Different comparison model for FokI, TaqI, BsmI, and ApaI were as follows: ***FokI***; dominant model (ff + Ff vs. FF), recessive model (ff vs. Ff + FF), allelic model (f vs. F), homozygote (ff vs. FF), and heterozygote (Ff vs. FF): ***TaqI***; dominant model (tt + Tt vs. TT), recessive model (tt vs. Tt + TT), allelic model (t vs. T), homozygote (tt vs. TT), and heterozygote (Tt vs. TT): ***BsmI***; dominant model (bb + Bb vs. BB), recessive model (bb vs. Bb + BB), allelic model (b vs. B), homozygote (bb vs. BB), and heterozygote (Bb vs. BB): ***ApaI***; dominant model (aa+Aa vs. AA), recessive model (aa vs. Aa+AA), allelic model (a vs. A), homozygote (aa vs. AA), and heterozygote (Aa vs. AA). The heterogeneity among studies was measured by the χ2 test-based Q statistic, and I^2^ value which quantify the degree of heterogeneity \[[@CR28]\]. Accordingly, heterogeneity was considered significant if I^2^ values exceeded 50% or the Q statistic had a *P* value of less than 0.1 and random-effects model (DerSimonian--Laird approach) was carried out \[[@CR29]\]. Otherwise, the fixed-effects model (Mantel--Haenszel approach) was performed for combination of data \[[@CR30]\]. In order to assess the predefined sources of heterogeneity among included studies, subgroup analysis and meta-regression analysis based on year of population, and ethnicity were performed. Stability of our results was assessed by sensitivity analysis. Potential publication bias was estimated by Egger's linear regression test, and also Begg's test was employed to estimate the funnel plot asymmetry (*P* value\< 0.05 considered statistically significant) \[[@CR31], [@CR32]\]. The data analyses were carried out using STATA (version 14.0; Stata Corporation, College Station, TX) and SPSS (version 23.0; SPSS, Inc. Chicago, IL).

Results {#Sec7}
=======

Study characteristics {#Sec8}
---------------------

Regarding to aforementioned keywords, a total of 1116 studies were initially retrieved. Of these studies, 456 publications were duplicate, 559 and 62 publications excluded by title & abstract and full text examination, respectively. Finally, 39 studies qualified for quantitative analysis. It should be noted that while the latest meta-analysis by Tizaouia et al. \[[@CR20]\] in 2014 included 23 studies, we performed the updated meta-analysis by adding 16 more articles. Also, no studies were found by hand search (Fig. [1](#Fig1){ref-type="fig"}**)**. The eligible studies were published from 1998 to 2019 and had an overall good methodological quality with NOS scores ranging from 6 to 8. Polymerase chain reaction-restriction fragment length polymorphism (PCR- RFLP) and Taq-man were used by majority of included studies as genotyping method. Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} summarized the characteristics and genotype frequency of the included studies. Fig. 1Flow diagram of study selection processTable 1Characteristics of studies included in meta-analysis of overall T1DMStudy authorYearCountryEthnicitySex cases/controlsTotal cases/controlAge case/control (Mean)Genotyping methodQuality\
score**FokI (rs2228570)** Ban et al. \[[@CR33]\]2001JapanAsianM = 50/60F = 100/150108 / 25026.0 ± 3.8 / NRRFLP-PCR7 Fassbender et al. \[[@CR34]\]2002GermanyEuropeanM = 42/33F = 27/3075 / 5734.1 ± 11.1 / 33.5 ± 10.1RFLP-PCR6 Gyorffy et al. \[[@CR35]\]2002HungaryEuropeanM = 57/50F = 53/50107 / 10323.5 ± 5.11 / NRRFLP-PCR7 Turpeinen (Turku) et al. \[[@CR36]\]2003FinlandEuropeanM = NRF=NR274 / 808NR / NRMini sequencing8 Turpeinen (Tampere) et al. \[[@CR36]\]2003FinlandEuropeanM = NRF=NR55 / 457NR / NRMini sequencing8 Turpeinen (Oulu) et al. \[[@CR36]\]2003FinlandEuropeanM = NRF=NR249 / 795NR / NRMini sequencing8 Audi (barcellona) et al. \[[@CR37]\]2004SpainEuropeanM = 69/86F = 153/122155 / 275NR / NRMini sequencing7 Audi (navarra) et al. \[[@CR37]\]2004SpainEuropeanM = 40/46F = 58/5886 / 116NR / NRMini sequencing7 San Pedro et al. \[[@CR38]\]2005SpainEuropeanM = NRF=NR71 / 8814.5 ± 9.9 / NRRFLP-PCR6 Zemunik et al. \[[@CR39]\]2005CroatiaEuropeanM = 72/62F=NR134 / 2328.6 ± 4.3 / NRRFLP-PCR7 Capoluongo et al. \[[@CR40]\]2006ItalyEuropeanM = 135/111F = 135/111246 / 24639.3 ± 11.1 / 39.6 ± 9.1RFLP-PCR8 Lemos et al. \[[@CR41]\]2008PortugalEuropeanM = 113/94F = 143/106207 / 24927.5 ± 10.2 / 36.8 ± 13.8RFLP-PCR8 Israni et al. \[[@CR42]\]2009IndiaAsianM = 131/135F = 116/81236 / 19715.1 ± 7.30 / 30.1 ± 10.2RFLP-PCR7 Mory et al. \[[@CR43]\]2009BrazilAmericanM = NRF=NR177 / 18217.2 ± 5.4 / 12.2 ± 8.1RFLP-PCR7 Panierakis et al. \[[@CR15]\]2009GreeceEuropeanM = NRF = 52/44100 / 96NR / NRMini sequencing6 Yavuz et al. \[[@CR44]\]2011turkeyEuropeanM = 60/57F = 73/61117 / 13427.6 ± 7.3 / 26.2 ± 5.3RFLP-PCR6 Yokota et al. \[[@CR45]\]2012JapanAsianM = NRF=NR108 / 220NR / NRNR7 Bonakdaran et al. \[[@CR46]\]2012IranAsianM = 28/41F = 19/2669 / 45NR / NRRFLP-PCR6 Sahin et al. \[[@CR47]\]2012TurkeyEuropeanM = NRF=NR85 / 80NR / NRNR6 Mohammadnejad et al. \[[@CR48]\]2012IranAsianM = 32/55F = 50/5087 / 10027.93 ± 10.86 / 28.58 ± 7.40RFLP-PCR6 Vedralova et al. \[[@CR49]\]2012CzechEuropeanM = NRF=NR116 / 11367.0 ± 12.44 / 45.0 ± 7.31RFLP-PCR6 Greer et al. \[[@CR50]\]2012AustraliaAustralianM = NRF=NR50 / 55NR / NRRFLP-PCR6 Hamed et al. \[[@CR51]\]2013EgyptAfricanM = 64/68F = 18/22132 / 408.5 ± 3.3 / 9.0 ± 1.5RFLP-PCR6 Abd-Allah et al. \[[@CR52]\]2014EgyptAfricanM = 42/78F = 42/78120 / 12011.7 ± 2.8 / 11.1 ± 2.6RFLP-PCR7 Kafoury et al. \[[@CR53]\]2014EgyptAfricanM = 25/35F=NR60 / 6011.2 ± 3.7 / 27.2 ± 6.4RFLP-PCR6 Nasreen et al. \[[@CR54]\]2016PakistanAsianM = 25/19F = 23/2144 / 4414.81 ± 2.7 / 17.92 ± 2.8RFLP-PCR6 Mukhtar et al. \[[@CR55]\]2017PakistanAsianM = NRF=NR102 / 10013/2 / 13/8RFLP-PCR6 Ali et al. \[[@CR56]\]2018Saudi ArabiaAsianM = 54/46F = 43/59100 / 10210.33 ± 3.15 / \> 35RFLP-PCR7 Rasoul et al. \[[@CR57]\]2019KuwaitAsianM = NRF=NR253 / 2148.5 ± 5.5 / 8.9 ± 5.2RFLP-PCR8**TaqI (rs731236)** Chang et al. \[[@CR58]\]2000ChinaAsianM = 71/86F = 156/92157 /24823.5 ± 5.11 / 32.4 ± 6.6RFLP-PCR8 Fassbender et al. \[[@CR34]\]2002GermanyEuropeanM = 57/50F = 53/5075 /575.8 ± 2.3 / NRRFLP-PCR6 Gyorffy et al. \[[@CR35]\]2002Hungary,EuropeanM = 57/50F = 53/50107 / 10323.5 ± 5.11 / NRRFLP-PCR7 Skrabic et al. \[[@CR59]\]2003CroatiaEuropeanM = 72/62F = 60/72134 / 1328.69 ± 4.3 / 8.24 ± 4.9RFLP-PCR7 Bianco et al. \[[@CR60]\]2004ItalyEuropeanM = NRF=NR31 / 36NR / NRRFLP-PCR6 San Pedro et al. \[[@CR38]\]2005SpainEuropeanM = NRF=NR71 / 8814.5 ± 9.9 / NRRFLP-PCR6 Garcia et al. \[[@CR61]\]2007ChileAmericanM = 120/96F = 106/97216 / 2039.3 ± 4.2 / 10.3 ± 2.5RFLP-PCR8 Lemos et al. \[[@CR41]\]2008PortugalEuropeanM = NRF=NR205 / 23227.5 ± 10.2 / 36.8 ± 13.8RFLP-PCR8 Israni et al. \[[@CR42]\]2009IndiaAsianM = 131/135F = 116/81236 / 19715.1 ± 7.30 / 30.1 ± 10.2RFLP-PCR7 Panierakis et al. \[[@CR15]\]2009GreeceEuropeanM = NRF = 52/44100 / 96NR / NRMini sequencing6 Yavuz et al. \[[@CR44]\]2011TurkeyEuropeanM = 60/57F = 73/61117 / 13427.6 ± 7.3 / 26.2 ± 5.3RFLP-PCR6 Bonakdaran et al. \[[@CR46]\]2012IranAsianM = 28/41F = 19/2669 / 45NR / NRRFLP-PCR6 Mohammadnejad et al. \[[@CR48]\]2012IranAsianM = 32/55F = 50/5087 / 10027.93 ± 10.86 / 28.58 ± 7.40RFLP-PCR6 Greer et al. \[[@CR50]\]2012AustraliaAustralianM = NRF=NR50 / 55NR / NRRFLP-PCR6 Abd-Allah et al. \[[@CR52]\]2014EgyptAfricanM = 42/78F = 42/78120 / 12011.7 ± 2.8 / 11.1 ± 2.6RFLP-PCR7 Cheon et al. \[[@CR62]\]2015KoreaAsianM = 35/46F = 53/6081 / 11310.28 ± 3.73 / 9.98 ± 3.56RFLP-PCR6 Khalid et al. \[[@CR63]\]2016Saudi ArabiaAsianM = NRF=NR100 / 5011.48 ± 3.39 / 9.50 ± 4.23RFLP-PCR6 Iyer et al. \[[@CR64]\]2017Saudi ArabiaAsianM = 25/25F = 25/2550 / 5025.37 ± 4.07 / 23.44 ± 5.38RFLP-PCR6 Rasoul et al. \[[@CR57]\]2019KuwaitAsianM = NRF=NR253 / 2148.5 ± 5.5 / 8.9 ± 5.2RFLP-PCR8 Ahmed et al. \[[@CR65]\]2019EgyptAfricanM = 24/25F = 26/2550 / 5011.16 ± 3.27 / 10.97 ± 2.77RFLP-PCR6**BsmI (rs1544410)** Hauache et al. \[[@CR66]\]1998BrazilAmericanM = NRF = 31/6378 / 9415.5 ± 6.0 / 49 ± 11RFLP-PCR6 Chang et al. \[[@CR58]\]2000ChinaAsianM = 71/86F = 156/92157 / 24823.5 ± 5.11 / 32.4 ± 6.6RFLP-PCR8 Fassbender et al. \[[@CR34]\]2002GermanyEuropeanM = 57/50F = 53/5075 / 575.8 ± 2.3 / NRRFLP-PCR6 Gyorffy et al. \[[@CR35]\]2002HungaryEuropeanM = 57/50F = 53/50107 / 10323.5 ± 5.11 / NRRFLP-PCR7 Motohashi et al. \[[@CR67]\]2002JapanAsianM = 96/107F = 101/121203 / 22234.6 ± 16.9 / 44.4 ± 13.7RFLP-PCR8 Skrabic et al. \[[@CR59]\]2003CroatiaEuropeanM = 72/62F = 60/72134 / 1328.69 ± 4.3 / 8.24 ± 4.9RFLP-PCR7 Turpeinen (Turku) et al. \[[@CR36]\]2003FinlandEuropeanM = NRF=NR220 / 844NR / NRMini sequencing8 Turpeinen (Tampere) et al. \[[@CR36]\]2003FinlandEuropeanM = NRF=NR58 / 1175NR / NRMini sequencing8 Turpeinen (Oulu) et al. \[[@CR36]\]2003FinlandEuropeanM = NRF=NR226 / 818NR / NRMini sequencing8 Audi (barcellona) et al. \[[@CR37]\]2004SpainEuropeanM = 69/84F = 153/121153 / 274NR / NRMini sequencing7 Audi (navarra) et al. \[[@CR37]\]2004SpainEuropeanM = 40/49F = 58/5889 /116NR / NRMini sequencing7 Bianco et al. \[[@CR60]\]2004ItalyEuropeanM = NRF=NR31 / 36NR / NRRFLP-PCR6 San Pedro et al. \[[@CR38]\]2005SpainEuropeanM = NRF=NR71 / 8814.5 ± 9.9 / NRRFLP-PCR6 Capoluongo et al. \[[@CR40]\]2006ItalyEuropeanM = 135/111F = 135/111246 / 24639.3 ± 11.1 / 39.6 ± 9.1RFLP-PCR8 Garcia et al. \[[@CR61]\]2007ChileAmericanM = NRF = 106/97208 / 2039.3 ± 4.2 / 10.3 ± 2.5RFLP-PCR8 Lemos et al. \[[@CR41]\]2008PortugalEuropeanM = NRF=NR207 / 24827.5 ± 10.2 / 36.8 ± 13.8RFLP-PCR8 Shimada et al. \[[@CR68]\]2008JapanAsianM = 357/417F=NR774 / 59929/8 / NRRFLP-PCR8 Israni et al. \[[@CR42]\]2009IndiaAsianM = 131/135F = 116/81236 / 19715.1 ± 7.30 / 30.1 ± 10.2RFLP-PCR7 Mory et al. \[[@CR43]\]2009BrazilAmericanM = NRF=NR177 / 18217.2 ± 5.4 / 12.2 ± 8.1RFLP-PCR7 Panierakis et al. \[[@CR15]\]2009GreeceEuropeanM = NRF = 52/44100 / 96NR / NRMini sequencing6 Yavuz et al. \[[@CR44]\]2011TurkeyEuropeanM = 60/57F = 73/61117 / 13427.6 ± 7.3 / 26.2 ± 5.3RFLP-PCR6 Tawfeek et al. \[[@CR69]\]2011Arabic SaudiAsianM = 0/30F = 0/1430 / 1435.7 ± 5.33 / 33.2 ± 4.06RFLP-PCR6 Bonakdaran et al. \[[@CR46]\]2012IranAsianM = 28/41F = 19/2669 / 45NR / NRRFLP-PCR6 Vedralova et al. \[[@CR49]\]2012CzechEuropeanM = NRF=NR104 / 8367.0 ± 12.44 / 45.0 ± 7.31RFLP-PCR6 Mohammadnejad et al. \[[@CR48]\]2012IranAsianM = 32/55F = 50/5087 / 10027.93 ± 10.86 / 28.58 ± 7.40RFLP-PCR6 Moubarak et al. \[[@CR70]\]2013SyriaAsianM = 25/30F = 24/2655 / 5013.75 ± 6.91 / 39.86 ± 11.66RFLP-PCR6 Abd-Allah et al. \[[@CR52]\]2014EgyptAfricianM = 42/78F = 42/78120 / 12011.7 ± 2.8 / 11.1 ± 2.6RFLP-PCR7 Kafoury et al. \[[@CR53]\]2014EgyptAfricianM = 25/35F=NR60 / 5611.2 ± 3.7 / 27.2 ± 6.4RFLP-PCR6 Cheon et al. \[[@CR62]\]2015KoreaAsianM = 35/46F = 53/6081 / 11310.28 ± 3.73 / 9.98 ± 3.56RFLP-PCR6 Khalid et al. \[[@CR63]\]2016Saudi ArabiaAsianM = NRF=NR100 / 5011.48 ± 3.39 / 9.50 ± 4.23RFLP-PCR6 Iyer et al. \[[@CR64]\]2017Saudi ArabiaAsianM = 25/25F = 25/2550 / 5025.37 ± 4.07 / 23.44 ± 5.38RFLP-PCR6 Ali et al. \[[@CR56]\]2018Saudi ArabiaAsianM = 54/46F = 43/59100 / 10210.33 ± 3.15 / \> 35RFLP-PCR7 Rasoul et al. \[[@CR57]\]2019KuwaitAsianM = NRF=NR253 / 2148.5 ± 5.5 / 8.9 ± 5.2RFLP-PCR8 Ahmed et al. \[[@CR65]\]2019EgyptAfricanM = 24/25F = 26/2550 / 5011.16 ± 3.27 / 10.97 ± 2.77RFLP-PCR6**ApaI (rs7975232)** Chang et al. \[[@CR58]\]2000ChinaAsianM = 71/86F = 156/92157 / 24823.5 ± 5.11 / 32.4 ± 6.6RFLP-PCR8 Gyorffy et al. \[[@CR35]\]2002HungaryEuropeanM = 57/50F = 53/50107 / 10323.5 ± 5.11 / NRRFLP-PCR7 Skrabic et al. \[[@CR59]\]2003CroatiaEuropeanM = 72/62F = 60/72134 / 1328.69 ± 4.3 / 8.24 ± 4.9RFLP-PCR7 Turpeinen (Turku) et al. \[[@CR36]\]2003FinlandEuropeanM = NRF=NR198 / 797NR / NRMini sequencing8 Turpeinen (Tampere) et al. \[[@CR36]\]2003FinlandEuropeanM = NRF=NR56 / 450NR / NRMini sequencing8 Turpeinen (Oulu) et al. \[[@CR36]\]2003FinlandEuropeanM = NRF=NR239 / 843NR / NRMini sequencing8 Bianco et al. \[[@CR60]\]2004ItalyEuropeanM = NRF=NR31 / 36NR / NRRFLP-PCR6 San Pedro et al. \[[@CR38]\]2005SpainEuropeanM = NRF=NR71 / 8814.5 ± 9.9 / NRRFLP-PCR6 Garcia et al. \[[@CR61]\]2007ChileAmericanM = NRF = 106/97213 / 2039.3 ± 4.2 / 10.3 ± 2.5RFLP-PCR8 Lemos et al. \[[@CR41]\]2008PortugalEuropeanM = NRF=NR205 / 23227.5 ± 10.2 / 36.8 ± 13.8RFLP-PCR8 Israni et al. \[[@CR42]\]2009IndiaAsianM = 131/135F = 116/81236 / 19715.1 ± 7.30 / 30.1 ± 10.2RFLP-PCR7 Panierakis et al. \[[@CR15]\]2009GreeceEuropeanM = NRF = 52/44100 / 96NR / NRMini sequencing6 Yavuz et al. \[[@CR44]\]2011TurkeyEuropeanM = 60/57F = 73/61117 / 13627.6 ± 7.3 / 26.2 ± 5.3RFLP-PCR6 Bonakdaran et al. \[[@CR46]\]2012IranAsianM = 28/41F = 19/2669 / 45NR / NRRFLP-PCR6 Mohammadnejad et al. \[[@CR48]\]2012IranAsianM = 32/55F = 50/5087 / 10027.93 ± 10.86 / 28.58 ± 7.40RFLP-PCR6 Greer et al. \[[@CR50]\]2012AustraliaAustralianM = NRF=NR50 / 55NR / NRRFLP-PCR6 Abd-Allah et al. \[[@CR52]\]2014EgyptAfricanM = 42/78F = 42/78120 / 12011.7 ± 2.8 / 11.1 ± 2.6RFLP-PCR7 Cheon et al. \[[@CR62]\]2015KoreaAsianM = 35/46F = 53/6081 / 11310.28 ± 3.73 / 9.98 ± 3.56RFLP-PCR6 Khalid et al. \[[@CR63]\]2016Saudi ArabiaAsianM = NRF=NR100 / 5011.48 ± 3.39 / 9.50 ± 4.23RFLP-PCR6 Nasreen et al. \[[@CR54]\]2016PakistanAsianM = 25/19F = 23/2144 / 4414.81 ± 2.7 / 17.92 ± 2.8RFLP-PCR6 Iyer et al. \[[@CR64]\]2017Saudi ArabiaAsianM = 25/25F = 25/2550 / 5025.37 ± 4.07 / 23.44 ± 5.38RFLP-PCR6 Mukhtar et al. \[[@CR55]\]2017PakistanAsianM = NRF=NR102 / 10013/2 / 13/8RFLP-PCR6 Rasoul et al. \[[@CR57]\]2019KuwaitAsianM = NRF=NR252 / 2148.5 ± 5.5 / 8.9 ± 5.2RFLP-PCR8 Ahmed et al. \[[@CR65]\]2019EgyptAfricanM = 24/25F = 26/2550 / 5011.16 ± 3.27 / 10.97 ± 2.77RFLP-PCR6*NR* not reported, *M* male, *F* femaleTable 2Distribution of genotype and allele among T1DM patients and controlsStudy authorT1DM casesHealthy controlP-HWEMAFFFFfffFfFFFfFfFf**FokI (rs2228570)**    Ban et al. \[[@CR33]\]505261526482138303021980.010.396    Fassbender et al. \[[@CR34]\]353010100501930868460.480.403    Gyorffy et al. \[[@CR35]\]32561912094344722115910.440.441    Turpeinen (Turku) et al. \[[@CR36]\]50150742502981024142926189980.010.617    Turpeinen (Tampere) et al. \[[@CR36]\]728204268612261703485660.290.619    Turpeinen (Oulu) et al. \[[@CR36]\]37114981883109336034254610440.90.656    Audi (barcellona) et al. \[[@CR37]\]696818206104105142283521980.040.36    Audi (navarra) et al. \[[@CR37]\]3545611557415322135970.510.418    San Pedro et al. \[[@CR38]\]31355974541398121550.760.312    Zemunik et al. \[[@CR39]\]4263291471217313623282182\< 0.0010.392    Capoluongo et al. \[[@CR40]\]891124529020291127283091830.090.371    Lemos et al. \[[@CR41]\]811012526315197114383081900.630.381    Israni et al. \[[@CR42]\]1427915363109116765308860.060.218    Mory et al. \[[@CR43]\]8081162411139167242491150.040.315    Panierakis et al. \[[@CR15]\]504371435764311159330.180.171    Yavuz et al. \[[@CR44]\]61461016866606311183850.320.317    Yokota et al. \[[@CR45]\]504612146705920141138302\< 0.0010.686    Bonakdaran et al. \[[@CR46]\]38256101371820756340.710.377    Sahin et al. \[[@CR47]\]543101393143289114460.190.287    Mohammadnejad et al. \[[@CR48]\]493351314355405150500.50.25    Vedralova et al. \[[@CR49]\]38601813696257612126100\< 0.0010.442    Greer et al. \[[@CR50]\]2121863372822578320.820.29    Hamed et al. \[[@CR51]\]249216140124828444360.0080.45    Abd-Allah et al. \[[@CR52]\]5850121667478384194460.80.191    Kafoury et al. \[[@CR53]\]23211667534112794260.0010.216    Nasreen et al. \[[@CR54]\]3212076122519069190.060.215    Mukhtar et al. \[[@CR55]\]8413518123100002000\< 0.0010    Ali et al. \[[@CR56]\]643331613979212179250.660.122    Rasoul et al. \[[@CR57]\]1783045386120146671359690.020.161**Study authorT1DM casesHealthy controlP-HWEMAFTTTtttTtTTTtttTtTaqI (rs731236)**    Chang et al. \[[@CR58]\]14215029915233141480160.130.032    Fassbender et al. \[[@CR34]\]343110995119201858560.020.491    Gyorffy et al. \[[@CR35]\]4634271268842273411195\< 0.0010.461    Skrabic et al. \[[@CR59]\]545525163105487212168960.040.363    Bianco et al. \[[@CR60]\]1018338241120542300.390.416    San Pedro et al. \[[@CR38]\]2436118458314314105710.880.403    Garcia et al. \[[@CR61]\]11579223091231216913311950.460.233    Lemos et al. \[[@CR41]\]7094412341769195462771870.020.403    Israni et al. \[[@CR42]\]91112332941788098192581360.150.345    Panierakis et al. \[[@CR15]\]345971277310642284108\< 0.0010.562    Yavuz et al. \[[@CR44]\]3758221321024166271481200.960.447    Bonakdaran et al. \[[@CR46]\]3428796422017857330.210.366    Mohammadnejad et al. \[[@CR48]\]32523116585941015941\< 0.0010.205    Greer et al. \[[@CR50]\]1826662382624576340.870.309    Abd-Allah et al. \[[@CR52]\]426612150903369181351050.060.437    Cheon et al. \[[@CR62]\]66150147151058021880.690.035    Khalid et al. \[[@CR63]\]6322151485219161554460.010.46    Iyer et al. \[[@CR64]\]191417524816161848520.010.52    Rasoul et al. \[[@CR57]\]969661288218156362234880\< 0.0010.186    Ahmed et al. \[[@CR65]\]04284258040104060\< 0.0010.6**Study authorT1DM casesHealthy controlP-HWEMAFBBBbbbBbBBBbbbBbBsmI (rs1544410)**    Hauache et al. \[[@CR66]\]1339266591124339671210.970.643    Chang et al. \[[@CR58]\]41613724290116231184780.220.963    Fassbender et al. \[[@CR34]\]143526638718251461530.370.464    Gyorffy et al. \[[@CR35]\]19464284130165334851210.530.587    Motohashi et al. \[[@CR67]\]126412788318149172513930.20.885    Skrabic et al. \[[@CR59]\]2458521061621774411081560.060.59    Turpeinen (Turku) et al. \[[@CR36]\]97972629114935438810210965920.780.35    Turpeinen (Tampere) et al. \[[@CR36]\]29227803653348815415547960.010.338    Turpeinen (Oulu) et al. \[[@CR36]\]90103332831694033051101111525\< 0.0010.32    Audi (barcellona) et al. \[[@CR37]\]21735911519146147812393090.130.563    Audi (navarra) et al. \[[@CR37]\]2043268395195344911410.650.607    Bianco et al. \[[@CR60]\]1314440221417545270.960.375    San Pedro et al. \[[@CR38]\]154016707217442778980.90.556    Capoluongo et al. \[[@CR40]\]621255924924361122632442480.890.504    Garcia et al. \[[@CR61]\]211107715226414741151023040.650.748    Lemos et al. \[[@CR41]\]43966818223256107852192770.040.558    Shimada et al. \[[@CR68]\]321655772291319712147113510630.80.887    Israni et al. \[[@CR42]\]79120372781945694472061880.530.477    Mory et al. \[[@CR43]\]6057601771773874701502140.620.587    Panierakis et al. \[[@CR15]\]23572010397384315119730.620.38    Yavuz et al. \[[@CR44]\]20574097137145961871810.960.675    Tawfeek et al. \[[@CR69]\]3189243618510180.360.642    Bonakdaran et al. \[[@CR46]\]14262954841611184347\< 0.0010.522    Vedralova et al. \[[@CR49]\]4347141337530332093730.070.439    Mohammadnejad et al. \[[@CR48]\]1136405811694546631370.660.685    Moubarak et al. \[[@CR70]\]72523397114261054460.740.46    Abd-Allah et al. \[[@CR52]\]276825122118485220148920.360.383    Kafoury et al. \[[@CR53]\]8133929914114119930.020.83    Cheon et al. \[[@CR62]\]0136813149141086220\< 0.0010.973    Khalid et al. \[[@CR63]\]5132171346619211059410.350.41    Iyer et al. \[[@CR64]\]8123028722612126436\< 0.0010.36    Ali et al. \[[@CR56]\]30452510595622812152520.0050.254    Rasoul et al. \[[@CR57]\]14183293651411206628306122\< 0.0010.285    Ahmed et al. \[[@CR65]\]83575149321808218\< 0.0010.19**Study authorT1DM casesHealthy controlP-HWEMAFAAAaaaAaAAAaaaAaApaI (rs7975232)**    Chang et al. \[[@CR58]\]167665108206131051301313650.160.735    Gyorffy et al. \[[@CR35]\]23275773141334525111950.210.461    Skrabic et al. \[[@CR59]\]66521618484516615168960.350.363    Turpeinen (Turku) et al. \[[@CR36]\]35106571762201524412047458490.0010.532    Turpeinen (Tampere) et al. \[[@CR36]\]1323204963692291523675330.250.592    Turpeinen (Oulu) et al. \[[@CR36]\]43115812012771653892897199670.090.573    Bianco et al. \[[@CR60]\]1811247151120542300.390.416    San Pedro et al. \[[@CR38]\]153719677528431799770.940.437    Garcia et al. \[[@CR61]\]54115442232034312535211195\< 0.0010.48    Lemos et al. \[[@CR41]\]551005021020068101632372270.040.489    Israni et al. \[[@CR42]\]851331830316960110272301640.030.416    Panierakis et al. \[[@CR15]\]3757613169235815104880.030.458    Yavuz et al. \[[@CR44]\]3658231301043570311401320.720.485    Bonakdaran et al. \[[@CR46]\]1352478601826162280.010.311    Mohammadnejad et al. \[[@CR48]\]27481210272275716111890.120.445    Greer et al. \[[@CR50]\]152411544612321156540.220.49    Abd-Allah et al. \[[@CR52]\]446511153873668161401000.060.416    Cheon et al. \[[@CR62]\]532444212093470521740.10.769    Khalid et al. \[[@CR63]\]49447142582621373270.640.27    Nasreen et al. \[[@CR54]\]1425553351525455330.150.375    Iyer et al. \[[@CR64]\]171617505018161652480.010.48    Mukhtar et al. \[[@CR55]\]432633112928601417228\< 0.0010.14    Rasoul et al. \[[@CR57]\]192312941589162371536167\< 0.0010.156    Ahmed et al. \[[@CR65]\]242247030371308713\< 0.0010.15*P-HWE P* value for Hardy--Weinberg equilibrium, *MAF* minor allele frequency of control group

Quantitative synthesis {#Sec9}
----------------------

### Meta-analysis of the association between FokI (rs2228570) polymorphism and T1DM risk {#Sec10}

Overall, 29 case-control studies with 3723 cases and 5578 controls were analyzed for assessment of FokI polymorphism and T1DM risk. Of 29 studies, 15 studies were conducted in European countries \[[@CR15], [@CR34]--[@CR36], [@CR38]--[@CR41], [@CR44], [@CR47], [@CR49], [@CR71]\], 9 studies were in Asian countries \[[@CR33], [@CR42], [@CR45], [@CR46], [@CR48], [@CR54]--[@CR57]\], 3 studies were in African population \[[@CR51]--[@CR53]\] and eventually one study in Australia \[[@CR50]\] and one study in American population \[[@CR43]\]. Among studies were performed in Europe, Audi et al. \[[@CR71]\] conducted an association study in different city of Spain (Barcelona and Navarra) and reported all data separately including genotype and allele frequency; thus we considered each population as a separate study. The pooled results revealed no significant association in overall population across all genotype models, meanwhile subgroup analysis according to ethnicity showed decreased risk of T1DM susceptibility in European population \[dominant model (OR = 0.86, 95% CI, 0.74--1.00, *P* = 0.05) and heterozygote contrast (OR = 0.86, 95% CI, 0.75--0.99, *P* = 0.04)\] and increased risk of T1DM susceptibility in African population under all genotype models; dominant model (OR = 2.06, 95% CI, 1.20--3.53, *P* = 0.008), recessive model (OR = 2.14, 95% CI, 1.03--4.43, *P* = 0.04), allelic model (OR = 1.17, 95% CI, 1.06--2.97, *P* = 0.02), ff vs. FF model (OR = 3.11, 95% CI, 1.44--6.69, *P* = 0.004), and Ff vs. FF model (OR = 1.81, 95% CI, 1.13--2.91, *P* = 0.01). Besides, susceptibility to T1DM in Asians compared to Africans and Europeans were not affected by FokI polymorphism (Fig. [2](#Fig2){ref-type="fig"}). The results of pooled ORs, heterogeneity tests and publication bias tests in different analysis models are shown in Table [3](#Tab3){ref-type="table"}. Fig. 2Pooled OR and 95% CI of individual studies and pooled data for the association between *ApaI* gene polymorphism and T1DM risk in heterozygote contrast (Aa vs. AA)Table 3Main results of pooled ORs in meta-analysis of Vitamin D Receptor gene polymorphismsGroupGenetic ModelCase/ControlTest of AssociationTest of HeterogenicityTest of publication bias(Begg's test)(Egger's test)OR95%CI (***P*** value)***I***^***2***^ (%)***P***ZPT***P*FokI (rs2228570)Overall**Dominant model3723 / 55780.920.79--1.08 (0.31)\< 0.001\< 0.0010.280.780.790.43Recessive model3723 / 55780.980.71--1.35 (0.91)\< 0.001\< 0.0011.430.151.280.21Allelic model3723 / 55780.960.81--1.14 (0.65)\< 0.001\< 0.0010.710.470.870.39ff vs. FF3723 / 55780.960.69--1.35 (0.83)\< 0.001\< 0.0011.700.091.780.08Ff vs. FF3723 / 55780.940.79--1.12 (0.49)\< 0.001\< 0.0011.190.231.230.22**European**Dominant model3723 / 5578**0.860.74--1.00 (0.05)**0.2680.268−0.150.880.330.74Recessive model2077 / 38491.000.77--1.30 (0.98)0.0110.0110.600.541.150.27Allelic model2077 / 38490.930.82--1.06 (0.28)0.0150.015- 0.050.960.690.50ff vs. FF2077 / 38490.900.67--1.20 (0.46)0.0460.0460.270.781.010.33**Ff vs. FF2077 / 38490.860.75--0.99 (0.04)**0.4350.4350.740.450.590.56**Asian**Dominant model2077 / 38490.760.55--1.05 (0.09)0.0150.015- 0.740.45−0.310.76Recessive model1107 / 12720.930.23--3.68 (0.91)\< 0.001\< 0.0011.650.093.260.02Allelic model1107 / 12720.780.46--1.33 (0.36)\< 0.001\< 0.001− 0.250.800.040.97ff vs. FF1107 / 12720.870.25--3.01 (0.82)\< 0.001\< 0.0011.950.053.010.03Ff vs. FF1107 / 12720.840.53--1.34 (0.47)\< 0.001\< 0.0010.490.620.500.63**African**Dominant model1107 / 1272**2.061.20--3.53 (0.008)**0.2250.225- 0.520.60−0.190.88Recessive model312 /220**2.141.03--4.43 (0.04)**0.3820.382- 0.520.60−0.600.65Allelic model312 /220**1.771.06--2.97 (0.02)**0.0570.0570.520.600.230.85ff vs. FF312 /220**3.111.44--6.69 (0.004)**0.4930.493- 1.570.11−1.650.34Ff vs. FF312 /220**1.811.13--2.91 (0.01)**0.3370.337- 0.520.600.030.98**TaqI (rs731236)Overall**Dominant model1873 / 18951.060.78 -- 1.45 (0.70)78.3\< 0.001− 0.450.65−1.610.12Recessive model1873 / 18950.910.66 -- 1.26(0.58)59.10.001−1.930.05−1.930.07Allelic model1873/ 18951.020.81 -- 1.29 (0.86)81.9\< 0.001−0.240.80− 0.960.34tt vs. TT1873 / 18950.900.58 -- 1.39 (0.62)72.9\< 0.001−2.140.03−2.650.01Tt vs.TT1873 / 189951.120.84-- 1.49 (0.45)70.7\< 0.001−0.390.69−1.040.31**European**Dominant model840 / 8780.820.59--1.13 (0.23)49.10.056−1.480.13−1.880.11Recessive model840 / 8780.780.50--1.21 (0.26)55.10.029−1.240.21−0.950.38Allelic model840 / 8780.920.76--1.11 (0.36)9.60.356−1.730.08−1.270.25tt vs. TT840 / 8780.750.44--1.27 (0.28)61.10.012−1.730.08−1.680.14Tt vs.TT840 / 8780.870.64--1.20 (0.40)39.80.114− 0.990.32−1.100.31**Asian**Dominant model1033 / 10171.400.75 -- 2.58 (0.28)85.7\< 0.00101−1.080.31Recessive model1033 / 10171.050.51 -- 2.16 (0.88)74.50.008−2.440.01−3.550.02Allelic model1033 / 10171.270.75 -- 2.14 (0.36)88.7\< 0.00101−0.750.45tt vs. TT1033 / 10171.030.37 -- 2.85 (0.95)85.4\< 0.001−1.690.09−3.100.03Tt vs.TT1033 / 10171.460.83 -- 2.58 (0.19)80.1\< 0.001− 0.830.40− 0.770.46**BsmI (rs1544410)Overall**Dominant model4826 / 71591.020.80-- 1.30 (0.88)76.3\< 0.001−0.250.800.480.63Recessive model4826 / 71590.940.80 -- 1.10 (0.45)52.9\< 0.0010.130.890.200.84Allelic model4826 / 71590.990.86 -- 1.15 (0.92)77.6\< 0.0010.210.830.160.87bb vs. BB4826 / 71590.960.75-- 1.23 (0.74)59.8\< 0.001−0.59−0.55−0.690.49Bb vs. BB4826 / 71591.070.88 -- 1.29 (0.52)53.9\< 0.001−0.190.84−0.580.56**European**Dominant model1938 / 44500.940.71--1.24 (0.66)71.0\< 0.001−0.250.800.890.39Recessive model1938 / 44501.000.85--1.19 (0.95)20.70.223−0.250.80−0.630.54Allelic model1938 / 44501.000.89--1.13 (0.93)41.70.046−0.350.72−0.750.46bb vs. BB1938 / 44500.990.80--1.23 (0.92)16.10.2730.050.96−0.570.57Bb vs. BB1938 / 44501.050.89--1.25 (0.56)15.00.286−0.450.65−0.990.34**Asian**Dominant model2195 /20041.050.61 -- 1.79 (0.87)77.8\< 0.001− 0.120.90−0.380.71Recessive model2195 /20041.020.73 -- 1.40 (0.92)65.7\< 0.001−0.380.700.180.86Allelic model2195 /20041.000.72 -- 1.38 (0.97)85\< 0.0010.380.700.240.81bb vs. BB2195 /20041.070.55 -- 2.09 (0.84)76.8\< 0.001−0.120.90−0.420.68Bb vs. BB2195 /20041.070.67 -- 1.71(0.77)63.5\< 0.0010.120.90−0.490.63**American**Dominant model463 / 479**0.570.39--0.84 (0.004)**0.00.7551.570.1114.10.04Recessive model463 / 479**0.620.41--0.94 (0.02)**50.50.1330.520.600.380.76Allelic model463 / 479**0.660.54--0.81 (\< 0.001)**0.00.5490.520.600.800.57bb vs. BB463 / 479**0.520.34--0.80 (0.003)**0.00.8760.520.600.060.96Bb vs. BB463 / 4790.660.41--1.05 (0.08)13.20.3160.520.601.560.36**African**Dominant model230 / 2262.410.63--9.18 (0.19)810.065−0.520.60−0.150.90Recessive model230 / 2260.990.52--1.89 (0.96)26.80.242−10.310.180.23Allelic model230 / 2261.630.65--4.08 (0.29)86.30.031−0.520.600.050.96bb vs. BB230 / 2261.180.26--5.25 (0.83)67.00.082−10.310.150.35Bb vs. BB230 / 2262.400.81--7.17 (0.11)63.90.141−0.520.60−0.160.89**ApaI (rs7975232)Overall**Dominant model2436 / 40741.030.82--1.29 (0.79)66.2\< 0.0010.250.800.620.54Recessive model2436 / 40741.030.90--1.17 (0.68)48.40.0050.240.810.200.84Allelic model2436 / 40741.050.90--1.23 (0.52)72.7\< 0.0010.990.320.980.34aa vs. AA2436 / 40741.020.77--1.33 (0.90)52.90.002−0.180.85−0.560.57Aa vs. AA2436 / 40740.910.80--1.04 (0.18)25.50.355−0.030.970.050.97**European**Dominant model1258/ 29130.910.70--1.18 (0.47)49.10.039−0.980.32−1.240.25Recessive model1258/ 29131.090.92--1.30 (0.32)56.90.013−0.630.53−0.280.78Allelic model1258/ 29130.990.81--1.21 (0.90)68.60.001−1.160.24−0.620.54aa vs. AA1258/ 29131.020.72--1.45 (0.91)53.10.024−1.700.08−1.030.33Aa vs. AA1258/ 29130.900.75--1.09 (0.29)29.50.174−1.700.08−2.230.05**Asian**Dominant model1178 / 11611.270.78--2.05 (0.34)77.4\< 0.0011.700.080.900.39Recessive model1178 / 11610.910.71--1.15 (0.42)52.00.0271.880.061.260.24Allelic model1178 / 11611.150.82--1.62 (0.40)82.2\< 0.0011.340.181.690.13aa vs. AA1178 / 11611.140.63--2.04 (0.66)64.80.0021.340.180.230.82Aa vs. AA1178 / 11610.920.72--1.18 (0.52)6.80.3791.460.141.350.22

### Meta-analysis of the association between TaqI (rs731236) polymorphism and T1DM risk {#Sec11}

There were 20 case-control studies with 1837 cases and 1895 controls concerning TaqI polymorphism and T1DM risk. Studies were performed in different population, 8 studies were in Europeans \[[@CR15], [@CR34], [@CR35], [@CR38], [@CR41], [@CR44], [@CR59], [@CR60]\], 8 studies in Asians \[[@CR42], [@CR46], [@CR48], [@CR57], [@CR58], [@CR62]--[@CR64]\], 2 studies in Africans \[[@CR52], [@CR65]\] and one study each was in Australia \[[@CR50]\] and Americans \[[@CR61]\]. Meta-analysis rejected any significant association between TaqI SNP and the risk of T1DM susceptibility. Moreover, the results of subgroup analysis by ethnicity were not significant under five genotype models. In subgroup analysis, since there was only one study for the Australians \[[@CR50]\], Americans \[[@CR61]\], and two studies for Africans \[[@CR52], [@CR65]\], these studies were excluded from the analysis. The results of pooled ORs, heterogeneity tests and publication bias tests in different analysis models are shown in Table [3](#Tab3){ref-type="table"}.

### Meta-analysis of the association between BsmI (rs1544410) polymorphism and T1DM risk {#Sec12}

To examining the association between *BsmI* polymorphism and T1DM risk, 34 case-control studies with 4826 cases and 7159 controls subjects were included. It was detected that 15 studies with 1938 cases and 4450 controls were performed in European countries \[[@CR15], [@CR34]--[@CR36], [@CR38], [@CR40], [@CR41], [@CR44], [@CR49], [@CR59], [@CR60], [@CR71]\] which among these 15 studies, Turpeinen et al. \[[@CR36]\] conducted an association study in different city of Finland (Turku, Tampere and Oulu) and reported all data separately, including genotype and allele frequency; thus we considered each population as a separate study. Moreover, 13 studies out of 34 eligible studies were carried out in Asian populations \[[@CR42], [@CR46], [@CR48], [@CR56]--[@CR58], [@CR62]--[@CR64], [@CR67]--[@CR70]\], 3 studies were in Americans \[[@CR43], [@CR61], [@CR66]\] and three studies were in Africans \[[@CR52], [@CR53], [@CR65]\]. No significant association between BsmI polymorphism and T1DM risk were found under all genotype models for the overall population. However, pooled results of subgroup analysis indicated markedly significant negative associations between BsmI SNP and the risk of T1DM susceptibility in American populations across all genotype models; dominant model (OR = 0.57, 95% CI, 0.39--0.84, *P* = 0.004), recessive model (OR = 0.62, 95% CI, 0.41--0.94, *P* = 0.02), allelic model (OR = 0.66, 95% CI, 0.54--0.81, *P* \< 0.001), bb vs. BB model (OR = 0.52, 95% CI, 0.34--0.80, *P* = 0.003), except Bb vs. BB model (OR = 0.66, 95% CI, 0.41--1.05, *P* = 0.08) (Fig. [3](#Fig3){ref-type="fig"}). No significant association was detected for European, Asian and African population. The results of pooled ORs, heterogeneity tests and publication bias tests in different analysis models are shown in Table [3](#Tab3){ref-type="table"}. Fig. 3Pooled odds ratio (OR) and 95% confidence interval of individual studies and pooled data for the association between FokI, BsmI gene polymorphism and T1DM risk in different ethnicity subgroups and overall populations for A; dominant model (FokI), B; Ff vs. FF Model (FokI), and C; Recessive Model (BsmI)

### Meta-analysis of the association between ApaI (rs7975232) polymorphism and T1DM risk {#Sec13}

Finally, 24 case-control studies with 2436 cases and 4074 controls were identified eligible for quantitative synthesis of the association between ApaI polymorphism and T1DM risk. Overall, 10 studies were conducted in Europe \[[@CR15], [@CR35], [@CR36], [@CR38], [@CR41], [@CR44], [@CR59], [@CR60]\], 10 studies were in Asia \[[@CR42], [@CR46], [@CR48], [@CR54], [@CR55], [@CR57], [@CR58], [@CR62]--[@CR64]\], 2 studies in Africa \[[@CR52], [@CR65]\] and one study each was in Australia \[[@CR50]\] and America \[[@CR61]\]. Because of limited number of studies performed in Australia, America and Africa these studies were excluded from subgroup analysis. The results demonstrated no significant association between the ApaI polymorphism and risk of T1DM in the overall population and ethnic-specific analysis (Fig. [3](#Fig3){ref-type="fig"}). The results of pooled ORs, heterogeneity tests and publication bias tests in different analysis models are shown in Table [3](#Tab3){ref-type="table"}.

Evaluation of heterogeneity and publication bias {#Sec14}
------------------------------------------------

During the meta-analysis of *VDR* gene polymorphism evidence of substantial to moderate heterogeneity was detected. However, partial heterogeneity was resolved while the data were stratified by ethnicity. Publication bias was evaluated by funnel plot, Begg's test and Egger's test. There was no obvious evidence of asymmetry from the shapes of the funnel plots (Fig. [4](#Fig4){ref-type="fig"}), and all *P* values of Begg's test and Egger's test were \> 0.05, which showed no evidences of publication biases. Fig. 4Begg's funnel plot for publication bias test. A; dominant model *FokI*. B; dominant model *TaqI*. C; dominant model *BsmI.* D; dominant model *ApaI*. Each point represents a separate study for the indicated association

Sensitivity analysis {#Sec15}
--------------------

The leave-one-out method was used in the sensitivity analysis to explore the effect of individual data on the pooled ORs. The significance of ORs was not altered through omitting any single study in the dominant model for FokI, TaqI, BsmI and ApaI SNPs, indicating that our results were statistically robust (Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Sensitivity analysis in present meta-analysis investigates the single nucleotide polymorphisms of Vitamin D Receptor contribute to risk for T1DM (A, *FokI*; B, *TaqI*; C, *BsmI*; D*, ApaI*)

Bayesian meta-regression analysis {#Sec16}
---------------------------------

Meta-regression and subgroup analyses were performed to explore potential sources of heterogeneity among included studies (Table [4](#Tab4){ref-type="table"}). The findings of meta-regression indicated that ethnicity can be the potential source of heterogeneity, therefore, subgroup analysis was performed to attenuate the effect of these parameters. (Fig. [6](#Fig6){ref-type="fig"}). Table 4Meta-regression analyses of potential source of heterogeneityHeterogeneity FactorCoefficientSET***P***-value95% CIULLL**FokI (rs2228570)Publication Year**Dominant model0.0370.0211.740.09- 0.0060.082Recessive model0.7630.3132.440.020.1171.410Allelic model0.0370.0182.070.040.0010.074ff vs. FF0.6310.2422.600.010.1301.131Ff vs. FF0.0320.0221.430.16−0.0140.078**Ethnicity**Dominant model0.3220.0813.970.0010.1550.489Recessive model−1.101.43−0.770.44−4.0631.85Allelic model0.2310.0733.150.0040.0800.382ff VS. FF−0.5911.134−0.520.60−2.9321.749Ff vs. FF0.2170.0972.230.030.0170.416**TaqI (rs731236)Publication Year**Dominant model0.0690.0371.830.08−0.0100.148Recessive model0.0200.0310.650.52−0.0460.087Allelic model0.0380.0261.470.15−0.0160.093tt vs. TT0.0630.0481.320.20−0.0390.166Tt vs.TT0.0640.0371.720.10−0.0140.142**Ethnicity**Dominant model−0.2490.207−1.200.24−0.6840.185Recessive model−0.1140.145−0.790.44− 0.4240.194Allelic model−0.1450.123−1.180.25−0.4040.113tt vs. TT−0.1670.253−0.660.51−0.7070.373Tt vs.TT−0.2500.200−1.250.22−0.6700.170**BsmI (rs1544410)Publication Year**Dominant model0.1420.0463.030.0050.0460.237Recessive model0.0310.0241.290.20−0.0180.081Allelic model0.0630.0252.540.010.0120.115bb vs. BB0.1030.0472.170.030.0060.200Bb vs. BB0.0950.0332.840.0080.0260.163**Ethnicity**Dominant model0.4820.2651.820.07−0.0581.023Recessive model−0.1330.139−0.960.34−0.4170.149Allelic model0.1520.1431.070.293−0.1380.444bb vs. BB−0.2740.280−0.980.33−0.8460.296Bb vs. BB0.3810.1882.030.05−0.0020.764**ApaI (rs7975232)Publication Year**Dominant model0.0980.0541.810.08−0.0140.211Recessive model0.0050.0300.180.86−0.0570.068Allelic model0.0520.0321.640.11−0.0130.119aa vs. AA0.0420.0420.980.33−0.0470.131Aa vs. AA0.0270.0191.370.18−0.0140.069**Ethnicity**Dominant model−0.1300.290−0.450.65−0.7330.471Recessive model−0.0860.175−0.490.62−0.4520.279Allelic model0.0070.1710.040.96−0.3480.362aa vs. AA−0.2790.243−1.150.26−0.7850.226Aa vs. AA0.0330.1030.320.74−0.1810.248Fig. 6Meta-regression plots of the association between *VDR* gene polymorphisms and risk of CAD based on; A: Publication year (Dominant model), B: Ethnicity (Recessive model), C: Publication year (Allelic model), C: Ethnicity (aa vs. AA model)

Discussion {#Sec17}
==========

In this study, we performed a systematic review and meta-analysis to achieve a vivid and exact approximation of the associations between the *VDR* gene polymorphisms, including FokI (rs2228570), TaqI (rs731236), BsmI (rs1544410), and ApaI (rs7975232) and susceptibility to T1DM. The findings of meta-analysis on 39 case--control studies, containing 29 studies with 3723 cases and 5578 controls for FokI, 20 studies with 1837 cases and 1895 controls for TaqI, 34 studies with 4826 cases and 7159 controls for BsmI, and 24 studies with 2436 cases and 4074 controls for ApaI, indicated no significant association of *VDR* gene polymorphisms with T1DM risk in overall population. That notwithstanding, the subgroup analysis resulted in identification of significant associations between FokI and BsmI polymorphism and T1DM in African and American population. Our study provided some beneficial points over previous studies. First, this meta-analysis included further studies with more sample size compared with the previous studies, conferring more conclusive results. Second, we performed subgroup analysis by ethnicity to indicated association of *VDR* gene polymorphisms with T1DM risk in different ethnical groups.

Over the course of past years, a bulk of studies has addressed the association of *VDR* gene polymorphisms and risk of T1DM throughout various populations, resulting in conflicting findings \[[@CR61], [@CR67]\]. Such discrepancies might stem from diversity in detection methods, differences in diagnostic criterions, clinical heterogeneity, small sample sizes, low statistical power, and interactions between genetic and environmental contributing factors according to variations in the geo-epidemiological factors. As a consequence, three previous meta-analyses by Guo et al. \[[@CR21]\] in 2006 \[including 11 studies for FokI (1424 cases and 3301 controls), 13 studies for BsmI (1601cases and 4207 controls), 9 studies for ApaI (1101 cases and 2805 controls), and 7 studies for TaqI (681 cases and 781 controls)\], Zhang et al. \[[@CR22]\] in 2012 \[T1DM cases and 4049 controls in 21 studies for BsmI, 2167 T1DM cases and 3402 controls in 17 studies for FokI, 1166 T1DM cases and 2328 controls in 11 studies for ApaI, and 1041 T1DM cases and 1137 controls in 8 studies for TaqI\], and Tizaouia et al. \[[@CR20]\] in 2014 (13 studies for TaqI, 23 studies for BsmI, 15 studies for ApaI, and 18 studies for FokI) were carried out to resolved the conundrum and attain an exact approximation. They indicated that *VDR* gene SNPs were not associated with T1DM risk, except than BsmI polymorphism association with T1DM predisposition that was observed in Zhang et al. \[[@CR22]\] study. Upon the latest meta-analysis published in 2014, several original association studies evaluated the role of *VDR* gene polymorphisms with T1DM risk. As a result, the necessity for performing an updated meta-analysis is sensed to come up with resolution of the limitations of individual association studies and to gain a much more valid and comprehensive pooled estimation on the association of *VDR* gene polymorphisms with T1D risk.

Previous meta-analysis performed by Tizaouia et al. \[[@CR20]\] in 2014 reported no significant association of *VDR* gene FokI polymorphism with risk of T1D. According to our meta-analysis, the pooled results in overall population across all genotype models demonstrated no significant association of *VDR* gene FokI polymorphism; nonetheless, subgroup analysis according to ethnicity showed a marginally-significant decreased susceptibility to T1DM in European population according to dominant genetic model and heterozygote comparison, while an increased risk of T1DM in African population according to all genotype models. In addition, our meta-analysis did not support any significant association between TaqI SNP and susceptibility to T1DM. Furthermore, the results of subgroup analysis according to ethnicity did not show any significant association in all genetic models. However, in the subgroup analysis, given that there was only one study in the Australian \[[@CR50]\] and American \[[@CR61]\] populations, and two studies in the African \[[@CR52], [@CR65]\] population, the subgroup analysis was not performed in these populations. In line with our findings, previous meta-analysis by Tizaouia et al. \[[@CR20]\] also did not show significant association of *VDR* gene TaqI polymorphism with risk of T1D. According to the previous meta-analysis, BsmI SNP was not the risk factor for T1D susceptibility. However, after excluding one study, a marginal significant (*P* = 0.051) association was found in the homozygous model. On the other side, our meta-analysis also revealed that BsmI polymorphism was not a risk for T1DM in all genetic models when all of the population were analyzed. Nonetheless, subgroup analysis demonstrated a strong negative significant association between BsmI SNP and the risk of T1DM in American population in all of the genetic model comparisons. Finally neither our meta-analysis nor the previous one by Tizaouia et al. \[[@CR20]\] found any significant association of ApaI polymorphism and T1DM risk in overall as well as subgroup analyses. Taken together, although our meta-analysis included further studies compared to the previous study, the overall analysis was almost the same. Nonetheless, our subgroup analysis indicated association of *VDR* genetic polymorphisms with T1DM risk in different ethnical groups.

In their meta-analysis, Tizaoui et al. \[[@CR20]\] indicated in the stratification analysis that publication year, age, gender, estimated VitD levels, and latitude modulated the association between *VDR* gene polymorphisms and T1D risk. Furthermore, another meta-analysis revealed a relationship between winter ultraviolet radiation (UVR) and *VDR* gene polymorphisms in T1DM, implying to the influence of the UVR on the association between *VDR* polymorphisms and T1DM susceptibility \[[@CR72]\]. During the four cooler months, it was observed that latitude strongly determines the available levels of VitD producing UV. As latitude increases, the amount of VitD producing UV decreases, which may prevent VitD synthesis in humans \[[@CR73]\]. As a result, the latitude of the locations in which the individuals live may impress the susceptibility to develop T1DM.

Despite we tried to conduct best meta-analysis of the VDR gene polymorphisms and susceptibility to RA, there was also a number of limitations that should be taken into account. First, there was significant heterogeneity across studies, which may lessen the certainty of the results. However, we tried to find and attenuate its effect by meta-regression and subgroup analysis. Consequently, heterogeneity was still an unavoidable problem that may influence the accuracy of the overall results. Second, only articles published in the English language were include in this meta-analysis. Third, our meta-analysis was based on crude approximation of the genetic variations regardless of adjusting the analysis by gender, age, VitD intake, and other environmental factors like exposure to sun light, as several studies noted the involvement of these parameters as well as gene-environment and gene-gene interactions in the susceptibility and of RA and we could not analyze it owing to a lack of published well-structured data.

Conclusion {#Sec18}
==========

In conclusion, this study was a systematic review and meta-analysis of 40 case--control association studies to come up with the clear estimation of the associations between the *VDR* gene SNPs \[FokI (rs2228570), TaqI (rs731236), BsmI (rs1544410), and ApaI (rs7975232)\] and susceptibility to T1DM. The findings of meta-analysis revealed no significant association of *VDR* gene SNPs with T1DM risk in the overall population. However, the subgroup analysis indicated significant associations between FokI and BsmI polymorphism and T1DM risk in African and American population. As a limitation, we did not evaluate a number of *VDR* gene SNPs that might act in interaction with environmental factors to determine the fate of T1DM pathogenicity. Further investigations on the VDR, above and beyond the genetic as well as traditional risk factors, may confer a possibility for identification of critical susceptibility factors in the disease development, which might be applicable in the personalized medicine for better and optimized therapy of T1DM patients.
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